EU Updates Brexit Advice On Changing UK Applicant For Ongoing Procedures
Executive Summary
The EU has updated its no-deal Brexit advice for drugs being evaluated through the mutual recognition and decentralized procedures. The advice explains the last-minute changes that companies can make in relation to ongoing or pending applications.
You may also be interested in...
EU Regulators Urge Pharma To Share Their Brexit Plans
Sponsors of medicines evaluated through the EU's decentralized procedure are being urged to share their plans regarding Brexit with national agencies as soon as possible to help with planning. The head of the Dutch Medicines Agency thinks that the human medicines sector can learn from the progress being made in the veterinary space on this front.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.